August 22, 2025

Supplementary Figure S4 from A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 and/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥Age 60 Years

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Phase 1b/2 trial evaluates TP-0903's impact on acute myeloid leukemia patients, indicating promising biomarker results.

Patients achieving CR showed significant changes in p-H2AX levels compared to non-responders, indicating potential effectiveness.
Spectral flow cytometry demonstrated p-H2AX as a pharmacodynamic biomarker across different response categories.
Analysis focused on patients aged 60 and older with untreated acute myeloid leukemia, highlighting a vulnerable population.
These findings suggest p-H2AX could be integral in assessing treatment response for targeted therapies in leukemia.

Eisenmann et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark